Resveratrol
Also called: trans-resveratrol, 3,5,4'-trihydroxystilbene
Resveratrol is a polyphenol found in grape skins and seeds, red wine, peanuts, pistachios, some berries and Japanese knotweed (Polygonum cuspidatum). It is usually consumed as a dietary supplement.
- Category
- Other
- Forms
- Purified resveratrol (sources include grapes and Japanese knotweed)
- Strongest evidence
- C Limited
- Reviewed
- 2026-10-28
Class 1 Well studied in people. A 2026 meta-analysis (Diabetes Metab Syndr Obes) included 12 RCTs (636 adults with type 2 diabetes) of oral resveratrol, 8 to 1,000 mg/day, versus placebo or no added treatment; one tested a grape extract containing resveratrol, and at least one (Bhatt 2012) was open-label without placebo. [4]
Fact-checked 2026-10-28 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
CHormones and reproduction2 topics
CHeart and blood vessels1 topic
CBlood sugar and weight1 topic
DSeveral areas, whole body or blood1 topic
XBrain, mood and sleep1 topic
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Blood sugar control in type 2 diabetes | C | A Cochrane review of 3 trials (50 adults; 10–1,000 mg/day for 4–5 weeks) found neutral effects on HbA1c, fasting glucose and insulin resistance; evidence was insufficient to judge efficacy or safety. [1] |
| Memory and cognition | X | A meta-analysis found no significant effect on memory or cognitive performance, and recent double-blind trials found no cognitive benefit in older adults. [2] |
| Cardiovascular risk factors | C | A meta-analysis found no benefit on cardiovascular risk factors; resveratrol did not lower all-cause mortality in older adults, and higher doses may raise cardiovascular risk biomarkers. [2] |
| Menopausal symptoms and well-being | C | In one long-term trial in postmenopausal women, resveratrol improved chronic pain, somatic menopausal symptoms, circulatory function and well-being. [2] |
| Hormonal migraine in premenopausal women | C | Resveratrol was ineffective in reducing hormonal migraine burden. [2] |
| Lifespan and aging | D | Marketing as an anti-aging supplement rests on longer life span in yeast cells; this effect has not been demonstrated in humans. [2] |
Amounts studied and limits
Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.
- 10 mg, 150 mg or 1,000 mg daily for 4–5 weeks in diabetes trials. [1]
No official upper intake level has been set.
Safety and side effects
- Liver (NIH LiverTox)Nothing found
No published information found in the sources checked.
Details and sources - Pregnancy and breastfeedingNothing found
No published information found in the sources checked.
Details and sources - Interactions with medicines3 listed
Antiplatelet drugs; Drugs metabolized by CYP3A4, CYP2D6, CYP2C9 or CYP1A2; Carbamazepine
Details and sources - Cancer evaluations (IARC, NTP)None found
No IARC or NTP evaluation was found in the lists checked.
Details and sources - FDA new dietary ingredient notifications4 on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographsNone found
No published information found in the sources checked.
Details and sources
- Mild to moderate gastrointestinal symptoms and diarrhea at high doses (2.5 and 5 g daily). [2]
- A study of a high-dose micronized formula in multiple myeloma was stopped because of serious adverse events, including kidney failure. [2]
- People with hormone-sensitive cancers should use caution: resveratrol has estrogen-like properties and activates estrogen and androgen receptor transcription. [2]
Interactions
| With | What happens |
|---|---|
| Antiplatelet drugs | Resveratrol inhibits platelet aggregation in vitro, so combined use may increase bleeding risk; clinical relevance has yet to be determined. [2] |
| Drugs metabolized by CYP3A4, 2D6, 2C9 or 1A2 | 1 g daily for 4 weeks inhibited CYP3A4, 2D6 and 2C9 and induced 1A2 in healthy volunteers, which can change levels of drugs these enzymes metabolize. [2] |
| Carbamazepine | In mice, a resveratrol-rich Polygonum cuspidatum supplement raised carbamazepine blood levels; clinical relevance has yet to be determined. [2] |
Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.
Regulatory status
- US: FDA states that, by law, it does not approve dietary supplements or their labeling before they are marketed; firms are responsible for the safety and labeling of their products. [3]
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
- Resveratrol (3,5,4'-trihydroxystilbene) Stilbenes (polyphenol) [P5]
US status
What FDA's published records show. FDA does not approve dietary supplements.
- FDA's published NDI notification list has 4 entries naming resveratrol (earliest NDI 100 submitted 2000-09-13; most recent NDI 653 submitted 2010-04-21). Each entry is one party's notification; the list gives the date of FDA's response letter but not what it said. [P1]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
Liver (NIH LiverTox)
- No published information found in the sources checked.
Interactions with medicines
- Antiplatelet drugs: Resveratrol inhibits platelet aggregation in vitro, so concurrent use may increase bleeding risk; clinical relevance is yet to be determined. [P5]
- Drugs metabolized by CYP3A4, CYP2D6, CYP2C9 or CYP1A2: In healthy volunteers, 1 g daily for 4 weeks inhibited CYP3A4, 2D6 and 2C9 and induced 1A2, so it can affect levels of drugs metabolized by these enzymes. [P5]
- Carbamazepine: In a murine model, Polygonum cuspidatum, a resveratrol-rich supplement, increased carbamazepine blood levels; clinical relevance has yet to be determined. [P5]
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
- No published information found in the sources checked.
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity test or examination of each dietary-ingredient component — 21 CFR 111.75(a)(1)(i) requires at least one appropriate test or examination to verify the identity of any component that is a dietary ingredient, unless FDA grants a petition-based exemption under 111.75(a)(1)(ii). [P4]
Supply and conservation
- Natural sources listed by MSK include grape skins and seeds, peanuts, pistachios, mulberries, blueberries, cranberries, and Polygonum cuspidatum (Japanese knotweed). [P5]
Absorption in people
- In six volunteers given 14C-resveratrol, absorption of a 25 mg oral dose was at least 70%, with peak plasma resveratrol plus metabolites of 491 +/- 90 ng/ml and a plasma half-life of 9.2 +/- 0.6 h, but only trace unchanged resveratrol (<5 ng/ml) was detected; rapid sulfate conjugation in the intestine and liver appears rate-limiting. [P6]
Formulations studied to change absorption
Human data only.
- Micronized resveratrol (SRT501, 5.0 g daily for 14 days in patients with colorectal cancer and hepatic metastases): mean plasma resveratrol after a single dose was 1,942 +/- 1,422 ng/mL, which the authors state exceeds published values for equivalent nonmicronized doses by 3.6-fold (comparison with published data, not a head-to-head arm). [P7]
- MSK: a study of a high-dose micronized formula in multiple myeloma patients was stopped because of serious adverse events. [P5]
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- No published information found in the sources checked.
Pregnancy and breastfeeding
- No published information found in the sources checked.
Sources for this profile
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- IARC Monographs. List of Classifications (list last updated 2026-07-23 per page data; checked 2026-10-29), 2026-07-23. monographs.iarc.who.int
- National Toxicology Program (NIEHS). Technical Reports list (checked 2026-10-29), 2026-10-29. ntp.niehs.nih.gov
- eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (up to date as of 10/23/2026), 2026-10-23. ecfr.gov
- Memorial Sloan Kettering Cancer Center. About Herbs: Resveratrol (Last Updated February 17, 2023), 2023-02-17. mskcc.org
- Walle T, et al. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 2004;32(12):1377-82 (PMID 15333514), 2004-12. pubmed.ncbi.nlm.nih.gov
- Howells LM, et al. Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases: safety, pharmacokinetics, and pharmacodynamics. Cancer Prev Res 2011;4(9):1419-25 (PMID 21680702), 2011-09. pubmed.ncbi.nlm.nih.gov
Sources
- Jeyaraman MM, et al. Resveratrol for adults with type 2 diabetes mellitus. Cochrane Database Syst Rev 2020;1:CD011919 (PMID 31978258), 2020-01-17. pubmed.ncbi.nlm.nih.gov
- Memorial Sloan Kettering Cancer Center. About Herbs: Resveratrol (Last Updated February 17, 2023), 2023-02-17. mskcc.org
- U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (content current as of 08/27/2026), 2026-08-27. fda.gov
- Gu W, et al. Resveratrol and Renal Biomarkers in Type 2 Diabetes: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials. Diabetes Metab Syndr Obes 2026;19:402309 (PMID 41878257), 2026. pubmed.ncbi.nlm.nih.gov
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in this category: Alpha-lipoic acid · Bee pollen · Beetroot juice (dietary nitrate) · Berberine · Beta-glucan (oat and barley) · Betaine (trimethylglycine) · Bromelain · Caffeine · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.